Ushering in Neoadjuvant Immune Checkpoint Inhibitors for Mucosal Head and Neck Squamous Cell Carcinoma

Producción científica: Comment/debate

1 Cita (Scopus)
Idioma originalEnglish
Páginas (desde-hasta)625-626
Número de páginas2
PublicaciónJAMA Otolaryngology - Head and Neck Surgery
Volumen151
N.º6
DOI
EstadoPublished - jun 12 2025

Financiación

Conflict of Interest Disclosures: Dr Saba reports personal fees from AstraZeneca, Eisai Medical, Exelixis/Merck, Merck, EMD Serono, Pfizer, Kura, Vaccinex, CUE, BionTech, GSK, TOSK, Seagen, Flamingo, Infinity, Inovio, Aveo, Medscape, Onclive, UpToDate, BMS, Cornerstone, Celldex, Surface Oncology, Urogen, Astex, Imugene, Faron Pharmaceutical, Coherus, Adagene, Fulgent Springer, Nanobiotix, and Taiho and funding from Exelixis and BMS outside the submitted work. No other disclosures were reported.

Financiadores
GlaxoSmithKline
TOSK
Exelixis Inc.
Bamfield Marine Sciences Centre

    ASJC Scopus subject areas

    • Surgery
    • Otorhinolaryngology

    Huella

    Profundice en los temas de investigación de 'Ushering in Neoadjuvant Immune Checkpoint Inhibitors for Mucosal Head and Neck Squamous Cell Carcinoma'. En conjunto forman una huella única.

    Citar esto